Mark L. Jacobson is COO at Axsome Therapeutics, Inc. (AXSM). They have made 2 open-market trades across 1 company since 2024, most recently 2026-09-03.
CIK 0001805812
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AXSM | 10,000 | $1.6M |
Shares reported on the most recent Form 4, priced at the 2026-09-03 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AXSM | SELL · 10b5-1 | 2026-09-03 | 2026-09-03 | $208.65 | $2.1M | +2.1% | -14.7% | — |
| AXSM | SELL · 10b5-1 | 2026-05-04 | 2026-05-05 | $227.95 | $1.1M | +1.5% | +3.1% | -5.9% |
| AXSM | SELL | 2026-02-26 | 2026-02-27 | $161.88 | $5.7M | -1.6% | -1.0% | +43.7% |
| AXSM | SELL · 10b5-1 | 2025-09-22 | 2025-09-22 | $115.96 | $1.2M | +2.1% | +10.4% | +31.7% |
| AXSM | SELL · 10b5-1 | 2025-09-16 | 2025-09-17 | $114.67 | $5.9M | +1.1% | +9.9% | +26.2% |
| AXSM | SELL · 10b5-1 | 2025-06-09 | 2025-06-10 | $110.44 | $2.8M | -7.9% | +0.4% | +17.2% |
| AXSM | SELL · 10b5-1 | 2025-05-27 | 2025-05-28 | $104.27 | $6.4M | +6.7% | +0.3% | +17.6% |
| AXSM | SELL · 10b5-1 | 2024-08-09 | 2024-08-09 | $84.26 | $8.0M | +5.8% | +13.2% | +9.1% |
| AXSM | SELL | 2024-05-29 | 2024-05-29 | $74.31 | $1.2M | -5.5% | +5.9% | +17.0% |
| AXSM | SELL · 10b5-1 | 2024-04-01 | 2024-04-01 | $77.24 | $3.8M | -5.5% | -1.3% | +6.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.